TAU targets drug-resistant ovarian tumors with nanotechnology
Ovarian cancer accounts for more deaths of American women than any other cancer of the female reproductive system. According to the American Cancer Society, one in 72 American women will be diagnosed with ovarian cancer, and one in 100 will ultimately die of the condition.
Now Prof. Dan Peer of Tel Aviv University‘s Department of Cell Research and Immunology has proposed a new strategy to tackle an aggressive subtype of ovarian cancer using a new nanoscale drug-delivery system designed to target specific cancer cells. He and his team — Keren Cohen and Rafi Emmanuel from Peer’s Laboratory of Nanomedicine and Einat Kisin-Finfer and Doron Shabbat, from TAU’s Department of Chemistry — have devised a cluster of nanoparticles called gagomers, made of fats and coated with a kind of polysugar. When filled with chemotherapy drugs, these clusters accumulate in tumors, producing dramatically therapeutic benefits.
The objective of Peer’s research is two-fold: to provide a specific target for anti-cancer drugs to increase their therapeutic benefits, and to reduce the toxic side effects of anti-cancer therapies. The study was published in February in the journal ACS Nano.
Why chemotherapy fails
According to Prof. Peer, traditional courses of chemotherapy are not an effective line of attack. Chemotherapy’s failing lies in the inability of the medicine to be absorbed and maintained within the tumor cell long enough to destroy it. In most cases, the chemotherapy drug is almost immediately ejected by the cancer cell, severely damaging the healthy organs that surround it, leaving the tumor cell intact.
But with their new therapy, Peer and his colleagues saw a 25-fold increase in tumor-accumulated medication and a dramatic dip in toxic accumulation in healthy organs. Tested on laboratory mice, the gagomer mechanism effects a change in drug-resistant tumor cells. Receptors on tumor cells recognize the sugar that encases the gagomer, allowing the binding gagomer to slowly release tiny particles of chemotherapy into the cancerous cell. As more and more drugs accumulate within the tumor cell, the cancer cells begin to die off within 24-48 hours.
“Tumors become resistant very quickly. Following the first, second, and third courses of chemotherapy, the tumors start pumping drugs out of the cells as a survival mechanism,” said Prof. Peer. “Most patients with tumor cells beyond the ovaries relapse and ultimately die due to the development of drug resistance. We wanted to create a safe drug-delivery system, which wouldn’t harm the body’s immune system or organs.”
The Latest on: Ovarian cancer
[google_news title=”” keyword=”Ovarian cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Ovarian cancer
- ImmunoGen bags priority review for full approval of ovarian cancer drugon December 5, 2023 at 3:55 am
The U.S. Food and Drug Administration has granted ImmunoGen (NASDAQ:IMGN) a priority review for its supplemental biologics license application of ovarian cancer drug Elahere (mirvetuximab soravtansine ...
- Allarity's Early Phase 2 Stenoparib Data Suggests Encouraging Results In Advanced Ovarian Canceron December 5, 2023 at 12:56 am
(RTTNews) - Allarity Therapeutics, Inc. (ALLR), Tuesday announced encouraging initial results from its ongoing Phase 2 clinical trial evaluating the efficacy of its PARP inhibitor Stenoparib, in women ...
- ImmunoGen Receives FDA's Priority Review For ELAHERE In Platinum-Resistant Ovarian Canceron December 5, 2023 at 12:04 am
ImmunoGen said now it is one step closer to securing full approval of ELAHERE in the US and establishing this novel ADC as the standard of care in FRa-positive platinum-resistant ovarian cancer. The ...
- Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnosticon December 4, 2023 at 11:30 pm
in women with advanced ovarian cancer (AOC). Of the five evaluable patients included in the initial data analysis, one patient experienced a complete response and the other four demonstrated stable ...
- Pacmilimab by CytomX Therapeutics for Ovarian Cancer: Likelihood of Approvalon December 4, 2023 at 9:10 pm
Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition ...
- PD-0360324 by Pfizer for Ovarian Cancer: Likelihood of Approvalon December 4, 2023 at 8:37 pm
PD-0360324 is under clinical development by Pfizer and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate ...
- Ovarian cancer victim may have survived with correct operationon December 4, 2023 at 1:36 pm
A woman who died with ovarian cancer may have survived if the correct operation had been carried out, an inquest has heard. Catherine Jones, a nurse at Wrexham Maelor hospital, had a cyst removed ...
- Dance-a-thon at Claremont Hotel raises awareness about ovarian canceron December 4, 2023 at 11:29 am
A weekend dance-a-thon at the Claremont Hotel and Spa in Berkeley raised more than $20,000 for ovarian cancer.
- After ovarian cancer diagnosis, an Oakland dancer is raising awarenesson November 28, 2023 at 8:59 am
Nina Schnall has been fighting ovarian cancer since 2020 and says there should be more conversation around the deadliest reproductive disease.
- Woman, 25, with ovarian cancer recalls symptoms that doctors dismissed: 'You’re fine'on November 28, 2023 at 7:46 am
A 25-year-old woman had pain in her side as a symptom of stage 2 low-grade serous ovarian cancer. She had a tumor on her ovary. Doctors said she was fine.
via Bing News